Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs6.12 B6.43 B6.44 B7.4 B8.59 B11.09 B11.56 BRecherche et développement6.09 B7.03 B7.19 B13.11 B14.27 B16.25 B16.04 BRésultat d'exploitation17.09 B18.11 B19.72 B24.72 B12.57 B25.99 B31.03 BTotal des produits hors exploitation1.17 B-201.6 M-320.9 M96.7 M-218.6 M-571 M-397 MCharges d'intérêts, nettes des intérêts capitalisés359.6 M339.8 M331.6 M485.9 M780.6 M895 M—Résultat hors exploitation, hors charges d'intérêts-434.4 M-592.8 M-638.2 M-356.5 M-193.2 M-571 M-116.6 MRevenus/dépenses exceptionnels1.25 B51.4 M-14.3 M-32.7 M-25.4 M——Résultat avant impôts7.23 B6.16 B6.81 B6.55 B12.68 B25.73 B31.13 BPart des actionnaires dans le résultat———————Impôts1.04 B573.8 M561.6 M1.31 B2.09 B5.09 B5.85 BIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts———————Résultat net avant activités abandonnées6.19 B5.58 B6.24 B5.24 B10.59 B20.64 B25.28 BActivités abandonnées00—————Résultat net6.19 B5.58 B6.24 B5.24 B10.59 B20.64 B25.28 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires6.19 B5.58 B6.24 B5.24 B10.59 B20.64 B25.28 BBénéfice par action de base (BPA de base)6.826.156.935.8211.762328.2Bénéfice par action dilué (BPA dilué)6.796.126.95.811.7122.9528.15Nombre moyen d'actions de base en circulation907.63 M906.96 M901.74 M900.18 M900.61 M897.3 M—Nombre d'actions en circulation après dilution912.5 M911.68 M904.62 M903.28 M904.06 M899.3 M—EBITDA18.41 B20.47 B21.24 B26.25 B14.34 B27.99 B33.08 BEBIT17.09 B18.11 B19.72 B24.72 B12.57 B25.99 B31.03 BCoût des ventes5.48 B7.31 B6.63 B7.08 B8.42 B11.05 B12.4 BAutres coûts des ventes—339.7 M—————Amortissements (flux de trésorerie)1.32 B1.55 B1.52 B1.53 B1.77 B2 B2.04 B
Eli Lilly and Company Common Stock
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes.